Valuation : Ardelyx, Inc.

Market Cap 942M 810M 762M 695M 1.3B 89.08B 1.3B 9.03B 3.49B 45.62B 3.54B 3.46B 145B P/E 2026 *
-21.2x
P/E 2027 * 16.3x
Enterprise Value 942M 810M 762M 695M 1.3B 89.08B 1.3B 9.03B 3.49B 45.62B 3.54B 3.46B 145B EV / Sales 2026 *
1.93x
EV / Sales 2027 * 1.51x
Free-Float
95.86%
Yield 2026 *
-
Yield 2027 * -
1 day-1.46%
1 month-5.50%
3 months-32.01%
6 months-38.93%
Current year-35.16%
1 week 3.68
Extreme 3.68
3.84
1 month 3.68
Extreme 3.68
4.12
Current year 3.68
Extreme 3.68
8.4
1 year 3.68
Extreme 3.68
8.4
3 years 3.16
Extreme 3.16
10.13
5 years 0.49
Extreme 0.4902
10.13
10 years 0.49
Extreme 0.4902
16.3
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2009
Director of Finance/CFO 55 04/11/2025
Chief Tech/Sci/R&D Officer 50 01/04/2026
Director TitleAgeSince
Director/Board Member 61 01/03/2009
Chairman 60 01/03/2014
Director/Board Member 59 01/03/2014
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/26 Sell

Chief Financial Officer

-1,558 0.0006%
21/08/26 Sell

Controller/Auditor

-3,982 0.0016%
21/08/26 Sell

Head of Human Resources

-15,136 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%0.00%-42.02%-16.74% 942M
-0.38%-0.99%+42.69%+100.85% 67.82B
-0.94%-3.05%+32.51%+77.26% 63.22B
-3.25%+3.67%-12.96%+374.95% 27.58B
-3.99%+2.12%-7.74%-13.34% 26.06B
+1.69%-0.36%+26.48%+15.46% 25.38B
+0.37%+0.93%+24.61%-17.76% 19.89B
+1.15%-5.02%+219.82%+379.02% 17.4B
-0.49%-0.37%-7.31%+524.84% 14.95B
-1.62%+8.00%+55.78%+167.98% 14.62B
Average -1.00%+1.43%+33.19%+159.25% 27.79B
Weighted average by Cap. -0.99%+0.89%+36.15%+139.06%

Financials

2026 *2027 *
Net sales 489M 420M 395M 361M 675M 46.23B 677M 4.69B 1.81B 23.67B 1.84B 1.8B 75.4B 624M 537M 505M 461M 862M 59B 864M 5.98B 2.31B 30.22B 2.34B 2.29B 96.25B
Net income -44.5M -38.27M -35.99M -32.86M -61.45M -4.21B -61.65M -427M -165M -2.16B -167M -163M -6.86B 62.15M 53.45M 50.27M 45.89M 85.83M 5.88B 86.11M 596M 230M 3.01B 233M 228M 9.59B
Net Debt - -
Logo Ardelyx, Inc.
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.
Employees
489
Date Price Change Volume
05/09/26 $3.780 +1.89% 2,982,312
03/09/26 $3.710 -2.37% 3,470,482
02/09/26 $3.800 +1.06% 3,913,811
01/09/26 $3.760 -0.53% 3,647,210
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.780USD
Average target price
12.90USD
Spread / Average Target
+241.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARDX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!